Cannabinoid | Moderate Risk

Cannabidiol (CBD) Oil 50mg/mL (Adaya CBD 50)

What to know about Cannabidiol (CBD) Oil 50mg/mL — also sold as Adaya CBD 50, Cannatrek C50, Beacon Medical CBD50: uses, side effects, interactions, and safety considerations for people taking it or caring for someone who is.

Cannabidiol (CBD) Oil 50mg/mL (brand names: Adaya CBD 50, Cannatrek C50, Beacon Medical CBD50) is classified as Moderate risk (5 risk points) by AllMeds. It is a S4 medication under the TGA in Australia. CBD-dominant, lower concentration

Key Takeaways

  • TGA Schedule: S4 in Australia
  • Risk level: Moderate (5 points)

Scheduling and Classification

Jurisdiction Classification Status
Australia (TGA) S4 Not PBS listed

Risk Profile

Risk Level Moderate
Risk Points 5
CNS Depressant No
Respiratory Risk No

CBD-dominant, lower concentration

How Cannabidiol (CBD) Oil 50mg/mL is regulated

Cannabidiol (CBD) Oil 50mg/mL is overseen by medicines regulators in each country. The rules below explain how it's scheduled, what oversight applies, and what to discuss with your doctor or pharmacist before starting, changing, or stopping this medication.

Australia TGA / PBS / State Schemes

Classified as S4 under the Therapeutic Goods Administration (TGA).

Clinical Evidence

  • Guidance for the Use of Medicinal Cannabis — TGA - TGA (2024)

    TGA clinical guidance on prescribing medicinal cannabis including CBD products. Covers indications, dosing, monitoring.

    Official TGA guidance

  • SIRA NSW Medication Management — Cannabis Medicines Section - SIRA NSW (2023)

    SIRA guidance on medicinal cannabis in workers comp. Requires prior authorisation, TGA SAS approval, and evidence of failed conventional treatment.

    NSW workers comp regulator — directly relevant to AllMeds use case

  • Cannabidiol for chronic pain: A systematic review and meta-analysis - Vela J, et al. (2022)

    Systematic review finding limited but emerging evidence for CBD in chronic pain. Most studies have small sample sizes and short duration.

    Peer-reviewed systematic review — notes evidence limitations

  • TGA: Access to Medicinal Cannabis — SAS Category 5 Pathway - TGA (2024)

    CBD products accessed via TGA SAS Category 5 (Authorised Prescriber) or SAS-B notification. Not registered on ARTG. Prescriber must be authorised.

    TGA regulatory framework for access

  • RACP Position Statement on Medicinal Cannabis - Royal Australasian College of Physicians (2023)

    RACP supports access via clinical trials and SAS but notes evidence is limited for most chronic pain indications.

    Peak Australian medical body

Check this medication against your full medication list

Run a full risk assessment including Cannabidiol (CBD) Oil 50mg/mL interactions and compliance checks.

Allmeds AI Pharmacist scans interactions, schedules, and risk flags across your entire medication profile in minutes. Free for individuals; team plans for case managers, insurers, and schemes.

Try it free → Talk to Sales →

Important: This page is general health information, not personal medical advice. If you have questions about your medication — including starting it, stopping it, changing the dose, or combining it with something else — speak with your doctor or pharmacist. For an emergency or suspected overdose, call your local emergency number or poison information service immediately. Information is drawn from regulator and clinical guideline sources (TGA, FDA, MHRA, NICE, PBS, CDC); see our methodology for details.